From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.

Curr Probl CardiolAug 12, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Abdulhakim M Alhazmi, Fakhr AlAyoubi, Rania E Mufti et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluates pharmacological therapies for obesity-driven heart failure with preserved ejection fraction (HFpEF). The review included 18 reports and found that sodium-glucose cotransporter 2 inhibitors are the most effective treatment, supported by mature outcome data. Semaglutide and tirzepatide also show benefits in improving symptoms and reducing heart failure events.

Key findings

  • Sodium-glucose cotransporter 2 inhibitors are recommended as the pharmacological foundation for obesity-driven HFpEF.
  • Semaglutide improves symptoms, physical limitations, exercise capacity, and body weight in HFpEF trials.
  • Tirzepatide reduces worsening heart failure events and improves clinical status.
  • Finerenone offers a broader therapeutic option, though obesity-specific data are indirect.

Why it matters

Understanding the pharmacological management of obesity-driven HFpEF is crucial for clinicians, as it highlights the need for a tailored approach that addresses both heart failure and underlying cardiometabolic dysfunction.

Source

PubMed · PMID 42586458

Published in Curr Probl Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.